Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Isis Expects To Submit Its Lipid-Lowering Treatment By Early 2009

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm has substantial interest from pharma companies looking to license the drug and expects to start an auction process “very soon,” Isis tells “The Pink Sheet” DAILY.

You may also be interested in...



Antisense Makes Financial Sense: Isis-Ortho-McNeil Pact Worth Potential $400 Mil.

Firms will co-develop up to four investigational drugs for metabolic diseases, including ISIS 325568 and ISIS 377131 for type 2 diabetes.

Antisense Makes Financial Sense: Isis-Ortho-McNeil Pact Worth Potential $400 Mil.

Firms will co-develop up to four investigational drugs for metabolic diseases, including ISIS 325568 and ISIS 377131 for type 2 diabetes.

Isis VP-Corporate Development Kate Winkler Corcoran: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Corcoran discusses firm’s strategy to license and develop specific targets developed through Isis’ proprietary RNA antisense technology.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS066046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By